Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial

Armenian SH, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S, Collier W, Su X, Marcus E, Echevarria M, Iukuridze A, Robison LL, Wong FL, Chen MH, Bhatia S. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. Lancet Oncol. 2024 Feb;25(2):235-245. doi: 10.1016/S1470-2045(23)00637-X. Epub 2024 Jan 9. PubMed PMID: 38215764; PubMed Central PMCID: PMC10872217.

Carvedilol improves cardiac function in patients with heart failure (HF) but remains untested as cardioprotective therapy in long-term childhood cancer survivors at risk for HF due to high-dose anthracycline exposure. We aimed to evaluate the activity and safety of low-dose carvedilol for HF risk reduction in childhood cancer survivors at highest risk for HF.